ArticleJournal of thrombosis and haemostasis : JTH2011
Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.
Article in Journal of thrombosis and haemostasis : JTH, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 97 citations in OpenAlex.
- Regenerative Medicine and Nanotechnology Approaches against Cardiovascular Diseases: Recent Advances and Future Prospective.Current stem cell research & therapy · 2025Review
- Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Application of nanomaterials in heart transplantation: a narrative review.Journal of thoracic disease · 2024Review
- Nanoparticles for Thrombus Diagnosis and Therapy: Emerging Trends in Thrombus-theranostics.Nanotheranostics · 2024Review
- Effective Prevention of Arterial Thrombosis with Albumin-Thrombin Inhibitor Conjugates.Molecular pharmaceutics · 2023Article
- Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction.International journal of molecular sciences · 2023Article
- Perfluorocarbons: A perspective of theranostic applications and challenges.Frontiers in bioengineering and biotechnology · 2023Review
- Theranostic nanoparticles for the management of thrombosis.Theranostics · 2022Review
- Sustained local inhibition of thrombin preserves renal microarchitecture and function after onset of acute kidney injury.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.International journal of nanomedicine · 2021Review
- Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases.Nanotheranostics · 2021Review
- Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis.Frontiers in cardiovascular medicine · 2021Review
- Bio- and Nanotechnology as the Key for Clinical Application of Salivary Peptide Histatin: A Necessary Advance.Microorganisms · 2020Review
- Targeted inhibition of thrombin attenuates murine neonatal necrotizing enterocolitis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Nanoparticles for "two color"Journal of colloid and interface science · 2020Article
- An unmet clinical need: The history of thrombus imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Review
- Antithrombin Perfluorocarbon Nanoparticles Improve Renal Allograft Function in a Murine Deceased Criteria Donor Model.Transplantation direct · 2018Article
- Quantification of vascular damage in acute kidney injury with fluorine magnetic resonance imaging and spectroscopy.Magnetic resonance in medicine · 2018Article
- Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAs a regulator of the penultimate step in the coagulation cascade, thrombin represents a principal target of direct and specific anticoagulants.
objectiveA potent thrombin inhibitor complexed with a colloidal nanoparticle was devised as a first-in-class anticoagulant with prolonged and highly localized therapeutic impact conferred by its multivalent thrombin-absorbing particle surface.
methodsPPACK (Phe[D]-Pro-Arg-Chloromethylketone) was secured covalently to the surface of perfluorocarbon-core nanoparticle structures. PPACK and PPACK nanoparticle inhibition of thrombin were assessed in vitro via thrombin activity against a chromogenic substrate. In vivo antithrombotic activity of PPACK, heparin, non-functionalized nanoparticles and PPACK nanoparticles was assessed through intravenous (i.v.) administration prior to acute photochemical injury of the common carotid artery. Perfluorocarbon particle retention in extracted carotid arteries from injured mice was assessed via (19) F magnetic resonance spectroscopy (MRS) and imaging (MRI) at 11.7 T. Activated partial thromboplastin time (APTT) measurements determined the systemic effects of the PPACK nanoparticles at various times after injection.
resultsAn optical assay verified that PPACK nanoparticles exceeded PPACK's intrinsic activity against thrombin. Application of an in vivo acute arterial thrombosis model demonstrated that PPACK nanoparticles outperformed both heparin (P=0.001) and uncomplexed PPACK (P = 0.0006) in inhibiting thrombosis. (19) F MRS confirmed that PPACK nanoparticles specifically bound to sites of acute thrombotic injury. APTT normalized within 20 min of PPACK nanoparticles injection.
conclusionsPPACK nanoparticles present thrombin-inhibiting surfaces at sites of acutely forming thrombi that continue to manifest local clot inhibition even as systemic effects rapidly diminish and thus represent a new platform for localized control of acute thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.